Initiated Outperform X

BCRX BioCryst Pharma

Wedbush

$15

Resumed Overweight X

BCRX BioCryst Pharma

JP Morgan

$10

Upgrades Sec Perform Outperform X

BCRX BioCryst Pharma

RBC Capital Mkts

$9 $10

Upgrades Hold Buy X

BCRX BioCryst Pharma

Jefferies

$11

Upgrades Neutral Buy X

BCRX BioCryst Pharma

BofA Securities

$10

Upgrades Hold Buy X

BCRX BioCryst Pharma

Needham

$14

Upgrades In-line Outperform X

BCRX BioCryst Pharma

Evercore ISI

$14 $16

Downgrades Outperform In-line X

BCRX BioCryst Pharma

Evercore ISI

$14

Downgrades Outperform Perform X

BCRX BioCryst Pharma

Oppenheimer

Downgrades Overweight Eq Weight X

BCRX BioCryst Pharma

Barclays

$22 $13

Downgrades Buy Neutral X

BCRX BioCryst Pharma

BofA Securities

$21 $14

Initiated Outperform X

BCRX BioCryst Pharma

Oppenheimer

$16

Initiated Outperform X

BCRX BioCryst Pharma

Cowen

$16

Downgrades Outperform Sec Perform X

BCRX BioCryst Pharma

RBC Capital Mkts

$16 $4.50

Resumed Overweight X

BCRX BioCryst Pharma

Piper Jaffray

$15

Resumed Overweight X

BCRX BioCryst Pharma

JP Morgan

$9

Upgrades Underperform Neutral X

BCRX BioCryst Pharma

BofA/Merrill

Initiated Neutral X

BCRX BioCryst Pharma

Seaport Global Securities

BCRX  BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.